Open AccessA phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
Author(s) -
Elena Élez,
Carles Pericay,
Manuel ValladaresAyerbes,
Inmaculada Bando,
María José Safont,
Javier Gállego,
Cristina Grávalos,
A. Arriví,
Alfredo Carrato,
V. Conde,
M. Ortiz,
Carlos López,
Beatriz Alonso,
I Mena,
Eduardo Dı́az-Rubio,
Josep Tabernero,
Enrique Aranda
Publication year - 2019
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-019-0537-z
Subject(s) - irinotecan , kras , medicine , panitumumab , oncology , colorectal cancer , neuroblastoma ras viral oncogene homolog , clinical endpoint , salvage therapy , cetuximab , bevacizumab , cancer , chemotherapy , clinical trial
Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patients.